On April 23, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, entitled "The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study," explores RenovoRx’s lead product candidate, intra-arterial delivery of gemcitabine via RenovoCath (known as IAG), and its potential to reduce systemic levels of the chemotherapy gemcitabine and increase levels of its inactive metabolite compared with intravenous gemcitabine. Additionally, the abstract studies IAG administration and its direct correlation between the metabolite levels and CA 19-9, a biomarker commonly used to assess potential chemotherapy response.
"This study provides important insights into how targeted intra-arterial delivery of chemotherapy may optimize drug distribution and pharmacologic activity in locally advanced pancreatic cancer," said Dr. Ramtin Agah, RenovoRx’s Executive Chairman and Chief Medical Officer, and study co-author. "We believe IAG has the potential to enhance effectiveness of therapeutic delivery while reducing systemic toxicity and common side effects."
The 2026 ASCO (Free ASCO Whitepaper) Annual Meeting will be held May 29 – June 2, 2026, in Chicago, Illinois, with the online publication of the abstract scheduled for May 21, 2026, at 5:00 P.M. ET.
Abstract Details:
Online Publication Date & Time: May 21, 2026, at 5:00 P.M. ET
Number for Publication: E16463
Title: The TIGeR-PaC Phase III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study.
(Press release, Renovorx, APR 23, 2026, View Source [SID1234664741])